HSD3B1 (1245A>C) germline variant and clinical outcomes in metastatic castration-resistant prostate cancer patients treated with abiraterone and enzalutamide: results from two prospective studies

Autor: Almagro, E., Arranz, J.Á., Billalabeitia, E.G., Borrega, P., Castro, E., Contreras, J.A., Domenech, M., Escribano, R., Fernández-Parra, E., Gallardo, E., García-Carbonero, I., García, R., Garde, J., González del Alba, A., González, B., Hernández, A., Hernando, S., Jiménez, P., Laínez, N., Lorente, D., Luque, R., Martínez, E., Medina, A., Méndez-Vidal, M.J., Montesa, A., Morales, R., Olmos David, Pérez-Gracia, J.L., Pérez-Valderrama, B., Pinto, Á., Piulats, J., Puente, J., Querol, R., Rodríguez-Vida, A., Romero-Laorden, N., Sáez, M.I., Vázquez, S., Vélez, E., Villa-Guzmán, J.C., Villatoro, R., Zambrana, C., Khalaf, D.J., Aragón, I.M., Annala, M., Lozano, R., Taavitsainen, S., Finch, D.L., Vergidis, J., Cendón, Y., Oja, C., Pacheco, M.I., Zulfiqar, M., Gleave, M.E., Wyatt, A.W., Olmos, D., Chi, K.N.

Publikováno v: In Annals of Oncology September 2020 31(9):1186-1197

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

The Challenge of Managing Bladder Cancer and Upper Tract Urothelial Carcinoma: A Review with Treatment Recommendations from the Spanish Oncology Genitourinary Group (SOGUG)

Autor: Font, A, Luque, R, Villa, JC, Domenech, M, Vazquez, S, Gallardo, E, Virizuela, JA, Beato, C, Morales-Barrera, R, Gelabert, A, Macia, S, Puente, J, Rubio, G, Maldonado, X, Perez-Valderrama, B, Pinto, A, Calvo, OF, Grande, E, Garde-Noguera, J, Fernandez-Parra, E, Arranz, JA

Publikováno v: TARGETED ONCOLOGY
r-FISABIO. Repositorio Institucional de Producción Científica
instname
r-FISABIO: Repositorio Institucional de Producción Científica
Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO)
Targeted Oncology
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol

Bladder cancer is the fourth most common cancer in men and the ninth most common in women in the Western world. The management of bladder carcinoma requires a multidisciplinary approach. Optimal treatment depends on several factors, including histolo

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::23318baf10540f9d531342f54b2480f3
https://fundanet.fisabio.san.gva.es/publicaciones/ProdCientif/PublicacionFrw.aspx?id=8426

Gemcitabine-erlotinib versus gemcitabine-erlotinib-capecitabine in the first-line treatment of patients with metastatic pancreatic cancer: Efficacy and safety results of a phase IIb randomised study from the Spanish TTD Collaborative Group

Autor: Irigoyen, A, Gallego, J, Guillen Ponce, C, Vera, R, Iranzo, V, Ales, I, Arevalo, S, Pisa, A, Martin, M, Salud, A, Falco, E, Saenz, A, Manzano Mozo, J, Pulido, G, Martinez Galan, J, Pazo-Cid, R, Rivera, F, Garcia Garcia, T, Serra, O, Fernandez Parra, E, Hurtado, A, Gomez Reina, M, Lopez Gomez, L, Martinez Ortega, E, Benavides, M, Aranda, E, Spanish Cooperative Grp Treatment

Publikováno v: EUROPEAN JOURNAL OF CANCER
r-FISABIO: Repositorio Institucional de Producción Científica
Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO)

Gemcitabine and erlotinib have shown a survival benefit in the first-line setting in metastatic pancreatic cancer (mPC). The aim of this study was to assess whether combining capecitabine (C) with gemcitabine + erlotinib (GE) was safe and effective v

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=RECOLECTA___::8b9abf8cc0b890f41f62a1d084e9ce13
https://fundanet.fisabio.san.gva.es/publicaciones/ProdCientif/PublicacionFrw.aspx?id=2026

894TiP - PROSTRATEGY: A Spanish Genitourinary Oncology Group (SOGUG) multi-arm multistage (MAMS) phase III trial of immunotherapy strategies in high-volume metastatic hormone-sensitive prostate cancer

Autor: Arija, J A Arranz, Valderrama, B.P., Gordoa, T Alonso, Diaz, E Gallardo, Sanchez, J M Sepulveda, Fernandez-Parra, E., Piulats, J.M., Vidal, M J Mendez, González, N Sala, Estevez, S Vazquez, Lainez, N., Zambrana, F., Quintela, M Lázaro, Duran, M A Climent, García-Carbonero, I., Diaz, C Caballero, Puente, J., Sánchez, J García, Virizuela, J.A., Carles, J.

Publikováno v: In Annals of Oncology October 2019 30 Supplement 5:v352-v353